MORPHOSYS Share Price Swiss Exchange
Equities
OXMOR
DE0006632003
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
67.65 EUR | 0.00% | 0.00% | 0.00% |
06/05 | MORPHOSYS : UBS reiterates its Neutral rating | ZD |
30/04 | European Equities Traded in the US as American Depositary Receipts Decline | MT |
Sales 2024 * | 12Cr 13Cr 1.11TCr | Sales 2025 * | 33Cr 35Cr 2.95TCr | Capitalization | 255.54Cr 277.74Cr 23TCr |
---|---|---|---|---|---|
Net income 2024 * | -43Cr -47Cr -3.9TCr | Net income 2025 * | -12Cr -13Cr -1.05TCr | EV / Sales 2024 * | 21.6 x |
Net Debt 2024 * | 8.93Cr 9.7Cr 808.83Cr | Net cash position 2025 * | 9.47Cr 10Cr 857.89Cr | EV / Sales 2025 * | 7.57 x |
P/E ratio 2024 * |
-6.01
x | P/E ratio 2025 * |
-32.6
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 84.39% |
Latest transcript on MORPHOSYS
Managers | Title | Age | Since |
---|---|---|---|
Jean-Paul Kress
CEO | Chief Executive Officer | 59 | 01/19/01 |
Lucinda Crabtree
DFI | Director of Finance/CFO | 45 | 07/23/07 |
Luisa Ciccarelli
CTO | Chief Tech/Sci/R&D Officer | - | 01/21/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Brosnan
BRD | Director/Board Member | 69 | 17/18/17 |
Director/Board Member | 67 | 17/18/17 | |
Marc Cluzel
CHM | Chairman | 69 | 31/12/31 |
1st Jan change | Capi. | |
---|---|---|
+26.90% | 4.92TCr | |
+0.99% | 4.21TCr | |
+50.47% | 4.04TCr | |
-5.26% | 2.89TCr | |
+13.80% | 2.61TCr | |
-22.32% | 1.87TCr | |
+7.73% | 1.33TCr | |
+32.50% | 1.23TCr | |
+0.29% | 1.2TCr |
- Stock Market
- Equities
- MOR Stock
- OXMOR Stock